SELL

Summary

SELL (selectin L, HGNC:10720) is a protein-coding gene on chromosome 1q24.2, encoding L-selectin (P14151). Calcium-dependent lectin that mediates cell adhesion by binding to glycoproteins on neighboring cells.

This gene encodes a cell surface adhesion molecule that belongs to a family of adhesion/homing receptors. The encoded protein contains a C-type lectin-like domain, a calcium-binding epidermal growth factor-like domain, and two short complement-like repeats. The gene product is required for binding and subsequent rolling of leucocytes on endothelial cells, facilitating their migration into secondary lymphoid organs and inflammation sites. Single-nucleotide polymorphisms in this gene have been associated with various diseases including immunoglobulin A nephropathy. Alternatively spliced transcript variants have been found for this gene.

Source: NCBI Gene 6402 — RefSeq curated summary.

At a glance

• GWAS associations: 11
• Clinical variants (ClinVar): 61 total — 1 pathogenic
• GTEx eGene: eQTL in 22 tissues, sQTL in 4 (q < 0.05)
• Drug target: yes — 2 curated mechanism-of-action drugs, 1 via a complex or family; 1 molecules with ChEMBL bioactivity
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.17 (unconstrained)
• MANE Select transcript: NM_000655
• Interaction hub: 2,780 STRING partners (top 3% of genes corpus-wide)
• Notable: 61 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10720
Approved symbol	SELL
Name	selectin L
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Aliases	LSEL, LAM1, LAM-1, hLHRc, Leu-8, Lyam-1, PLNHR, CD62L
Ensembl gene	ENSG00000188404
Ensembl biotype	protein_coding
OMIM	153240
Entrez	6402

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 8 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron

MANE Select: ENST00000236147

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 1, TSL 3: 1, TSL 5: 2

ENST00000236147, ENST00000460650, ENST00000463108, ENST00000466340, ENST00000479657, ENST00000497295, ENST00000650983, ENST00000878074, ENST00000878075, ENST00001099194, ENST00001099195, ENST00001145748

RefSeq mRNA: 1 — MANE Select: NM_000655 NM_000655

CCDS: CCDS53427

Canonical transcript exons

ENST00000236147 — 9 exons

Exon	Start	End
ENSE00000789630	169701560	169701688
ENSE00001131673	169690667	169691802
ENSE00003486796	169710436	169710517
ENSE00003523497	169707342	169707449
ENSE00003525031	169711496	169711620
ENSE00003554358	169696535	169696553
ENSE00003617246	169704568	169704753
ENSE00003661854	169703255	169703440
ENSE00003672522	169708417	169708803

Expression profiles

Bgee: expression breadth ubiquitous, 216 present calls, max score 99.63.

FANTOM5 (CAGE): breadth broad, TPM avg 67.1180 / max 7235.4291, expressed in 451 samples.

Highest expression (Bgee): blood, monocyte, leukocyte, mononuclear cell, granulocyte.

Genetic regulation across tissues (GTEx eQTL / sQTL)

SELL is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 22 tissues and its splicing (sQTL) in 4 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 26 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Whole Blood	eqtl	7.9e-23	-0.15	1:169601894:C:CA
Nerve Tibial	eqtl	1.4e-18	-0.43	1:169650353:C:G
Brain Caudate basal ganglia	eqtl	1.2e-10	-0.44	1:169646529:C:A
Whole Blood	sqtl	4.0e-10	-1.09	1:169691798:T:C
Brain Nucleus accumbens basal ganglia	eqtl	2.6e-09	-0.37	1:169666187:G:A
Brain Hippocampus	eqtl	1.4e-08	-0.41	1:169666187:G:A
Brain Putamen basal ganglia	eqtl	3.5e-08	-0.50	1:169646529:C:A
Cells EBV-transformed lymphocytes	eqtl	1.5e-06	-0.32	1:169691640:A:G
Brain Hypothalamus	eqtl	6.7e-06	-0.39	1:169660850:A:G
Brain Spinal cord cervical c-1	eqtl	5.7e-04	-0.43	1:169615283:T:C
Adipose Visceral Omentum	eqtl	7.4e-04	-0.13	1:169696491:T:C
Lung	eqtl	1.6e-03	-0.12	1:169695726:A:G
Brain Cortex	eqtl	1.7e-03	-0.25	1:169672590:A:G
Esophagus Muscularis	eqtl	3.5e-03	+0.85	1:168861185:C:A
Nerve Tibial	sqtl	4.2e-03	-0.91	1:168895980:A:G
Lung	sqtl	5.6e-03	-1.24	1:170214776:G:C
Brain Frontal Cortex BA9	eqtl	7.1e-03	-0.24	1:169633003:G:T
Esophagus Mucosa	eqtl	1.5e-02	-0.50	1:169145497:G:A
Small Intestine Terminal Ileum	eqtl	1.7e-02	+0.40	1:169790933:G:A
Spleen	eqtl	2.1e-02	+0.23	1:169578479:G:A

FANTOM5 promoters

5 alternative TSS:

Promoter ID	TPM avg	Samples expressed
15860	63.2334	444
15859	2.3393	173
15858	1.4166	147
15856	0.0900	12
15857	0.0386	22

Top tissues by expression

showing 100 of 281 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	99.63	gold quality
monocyte	CL:0000576	99.50	gold quality
leukocyte	CL:0000738	99.49	gold quality
mononuclear cell	CL:0000842	99.49	gold quality
granulocyte	CL:0000094	99.19	gold quality
bone marrow	UBERON:0002371	98.36	gold quality
vermiform appendix	UBERON:0001154	98.09	gold quality
bone marrow cell	CL:0002092	97.72	gold quality
spleen	UBERON:0002106	97.40	gold quality
trabecular bone tissue	UBERON:0002483	97.24	gold quality
lymph node	UBERON:0000029	96.70	gold quality
periodontal ligament	UBERON:0008266	96.13	gold quality
caecum	UBERON:0001153	91.15	gold quality
nasopharynx	UBERON:0001728	90.10	gold quality
epithelium of nasopharynx	UBERON:0001951	90.10	gold quality
gall bladder	UBERON:0002110	89.23	gold quality
thymus	UBERON:0002370	88.30	gold quality
right lung	UBERON:0002167	87.71	gold quality
superficial temporal artery	UBERON:0001614	85.80	gold quality
upper lobe of left lung	UBERON:0008952	85.32	gold quality
tonsil	UBERON:0002372	84.34	gold quality
upper lobe of lung	UBERON:0008948	83.78	gold quality
colonic epithelium	UBERON:0000397	82.05	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.64	gold quality
pituitary gland	UBERON:0000007	81.07	gold quality
adenohypophysis	UBERON:0002196	79.91	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	79.20	gold quality
rectum	UBERON:0001052	79.12	gold quality
hindlimb stylopod muscle	UBERON:0004252	78.66	gold quality
spinal cord	UBERON:0002240	78.26	gold quality
palpebral conjunctiva	UBERON:0001812	78.17	gold quality
parietal pleura	UBERON:0002400	78.10	gold quality
lung	UBERON:0002048	78.09	gold quality
adipose tissue of abdominal region	UBERON:0007808	77.02	gold quality
omental fat pad	UBERON:0010414	76.95	gold quality
peritoneum	UBERON:0002358	76.85	gold quality
smooth muscle tissue	UBERON:0001135	76.80	gold quality
right coronary artery	UBERON:0001625	76.71	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	76.24	gold quality
ileal mucosa	UBERON:0000331	75.61	gold quality
small intestine Peyer’s patch	UBERON:0003454	74.71	gold quality
nasal cavity mucosa	UBERON:0001826	74.67	gold quality
pleura	UBERON:0000977	74.59	gold quality
mucosa of transverse colon	UBERON:0004991	73.21	gold quality
descending thoracic aorta	UBERON:0002345	73.06	gold quality
left uterine tube	UBERON:0001303	73.00	gold quality
germinal epithelium of ovary	UBERON:0001304	72.67	gold quality
nasal cavity epithelium	UBERON:0005384	72.18	silver quality
small intestine	UBERON:0002108	71.40	gold quality
left coronary artery	UBERON:0001626	70.92	gold quality
ascending aorta	UBERON:0001496	70.86	gold quality
right lobe of liver	UBERON:0001114	70.83	gold quality
thoracic aorta	UBERON:0001515	70.67	gold quality
decidua	UBERON:0002450	70.64	silver quality
mucosa of paranasal sinus	UBERON:0005030	70.60	silver quality
coronary artery	UBERON:0001621	69.72	gold quality
substantia nigra	UBERON:0002038	69.54	gold quality
lower lobe of lung	UBERON:0008949	69.52	gold quality
subcutaneous adipose tissue	UBERON:0002190	69.29	gold quality
adipose tissue	UBERON:0001013	69.21	gold quality
urinary bladder	UBERON:0001255	69.13	gold quality
cranial nerve II	UBERON:0000941	69.09	gold quality
connective tissue	UBERON:0002384	69.07	gold quality
aorta	UBERON:0000947	68.97	gold quality
liver	UBERON:0002107	68.81	gold quality
tibial nerve	UBERON:0001323	68.77	gold quality
right atrium auricular region	UBERON:0006631	68.34	gold quality
popliteal artery	UBERON:0002250	67.99	gold quality
tibial artery	UBERON:0007610	67.98	gold quality
heart left ventricle	UBERON:0002084	67.47	gold quality
placenta	UBERON:0001987	67.01	gold quality
right lobe of thyroid gland	UBERON:0001119	66.98	gold quality
visceral pleura	UBERON:0002401	66.91	gold quality
midbrain	UBERON:0001891	66.86	gold quality
cardiac ventricle	UBERON:0002082	66.84	gold quality
heart	UBERON:0000948	66.83	gold quality
cardiac atrium	UBERON:0002081	66.78	gold quality
inferior vagus X ganglion	UBERON:0005363	66.69	gold quality
apex of heart	UBERON:0002098	66.58	gold quality
amniotic fluid	UBERON:0000173	66.33	silver quality
hypothalamus	UBERON:0001898	66.32	gold quality
metanephros cortex	UBERON:0010533	65.85	gold quality
amygdala	UBERON:0001876	65.83	gold quality
anatomical system	UBERON:0000467	65.77	gold quality
caudate nucleus	UBERON:0001873	65.72	gold quality
multicellular organism	UBERON:0000468	65.70	gold quality
intestine	UBERON:0000160	65.69	gold quality
material anatomical entity	UBERON:0000465	65.68	gold quality
inferior olivary complex	UBERON:0002127	65.57	silver quality
oral cavity	UBERON:0000167	65.42	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	65.39	silver quality
putamen	UBERON:0001874	65.37	gold quality
thyroid gland	UBERON:0002046	64.75	gold quality
left lobe of thyroid gland	UBERON:0001120	64.59	gold quality
sural nerve	UBERON:0015488	64.23	silver quality
lateral globus pallidus	UBERON:0002476	64.18	silver quality
gastrocnemius	UBERON:0001388	64.00	gold quality
calcaneal tendon	UBERON:0003701	63.92	gold quality
prefrontal cortex	UBERON:0000451	63.91	gold quality
large intestine	UBERON:0000059	63.90	gold quality

Single-cell (SCXA)

Detected in 28 experiment(s), a significant marker in 23.

Experiment	Marker?	Max mean expression
E-CURD-89	yes	1702.82
E-CURD-6	yes	1171.64
E-GEOD-110499	yes	1141.06
E-MTAB-9067	yes	1066.31
E-MTAB-6701	yes	812.67
E-CURD-79	yes	678.86
E-CURD-95	yes	673.27
E-MTAB-8911	yes	526.97
E-CURD-88	yes	518.68
E-HCAD-1	yes	98.33
E-CURD-122	yes	88.75
E-HCAD-8	yes	55.66
E-CURD-120	yes	52.45
E-HCAD-6	yes	44.43
E-HCAD-10	yes	30.97

HPA expression

RNA tissue specificity: Group enriched

showing 60 of 74 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Lymph node	tissue	216.7	high
Tonsil	tissue	189.4	high
Spleen	tissue	157.1	high
Bone marrow	tissue	142.1	high
Thymus	tissue	123.3
Appendix	tissue	112.1	high
Urinary bladder	tissue	35.4	not detected
Adipose tissue	tissue	27.4	not detected
Parathyroid gland	tissue	26.4	not detected
Gallbladder	tissue	22.6	not detected
Pituitary gland	tissue	13.9
Smooth muscle	tissue	13.5	not detected
Lung	tissue	13.5	not detected
Tongue	tissue	12.7
Liver	tissue	11.3	not detected
Placenta	tissue	10.5	not detected
Rectum	tissue	6.7	not detected
Colon	tissue	6.4	not detected
Small intestine	tissue	5.6	not detected
Stomach 1	tissue	5.3	not detected
Esophagus	tissue	5.2	not detected
Locus coeruleus	tissue	4.7
Fallopian tube	tissue	4.2	not detected
Hippocampus	tissue	3.8	not detected
Salivary gland	tissue	3.6	not detected
Cervix	tissue	3.5	not detected
Pancreas	tissue	3.5	not detected
Prostate	tissue	3.5	not detected
Skeletal muscle	tissue	3.2	not detected
Nucleus accumbens	tissue	3.1
Duodenum	tissue	3.0	not detected
Heart muscle	tissue	2.9	not detected
Choroid plexus	tissue	2.9
Olfactory bulb	tissue	2.9
Kidney	tissue	2.8	not detected
Breast	tissue	2.4	not detected
Endometrium 1	tissue	2.4	not detected
Spinal cord	tissue	2.3
Adrenal gland	tissue	2.2	not detected
Substantia nigra	tissue	2.0
Superior colliculi	tissue	1.9
Seminal vesicle	tissue	1.8	not detected
Thyroid gland	tissue	1.8	not detected
Thalamus	tissue	1.7
Epididymis	tissue	1.6	not detected
Medulla oblongata	tissue	1.6
Vagina	tissue	1.4	not detected
Putamen	tissue	1.4
Hippocampal formation	tissue	1.4
Entorhinal cortex	tissue	1.4
Cerebral cortex	tissue	1.3	not detected
Pons	tissue	1.3
Motor cortex	tissue	1.3
Midbrain	tissue	1.3
Insular cortex	tissue	1.3
Amygdala	tissue	1.2
Retrosplenial cortex	tissue	1.2
Prefrontal cortex	tissue	1.1
Ovary	tissue	1.1	not detected
Corpus callosum	tissue	1.1

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Cerebellar nuclei (14.6), Cerebellar white matter (12.8), Inferior olive (12.5), Dorsal funiculus (white matter) (12.0), Area parastriata, superior (11.1).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ETS1, FOXO1, IKZF1, IRF1, KLF2, MZF1, SP1

miRNA regulators (miRDB)

Targeting SELL by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 65 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-3681-5P	99.82	66.88	387
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-12130	99.75	65.47	452
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-4690-5P	99.65	66.24	813
HSA-MIR-6849-5P	99.64	66.00	352
HSA-MIR-4666B	99.64	68.69	1282
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-105-5P	99.54	69.24	2060
HSA-MIR-7853-5P	99.54	69.30	2055

Functional genomics

gnomAD constraint: pLI 1.54e-10, LOEUF 1.17, missense Z -0.347 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000236147 — one region, missense o/e 1.03.

Literature-anchored findings (GeneRIF, showing 40)

• The cytoplasmic domain of L-selectin regulates shedding by a mechanism in which bound calmodulin may operate as a negative effector. (PMID:11466384)
• interacts with oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) (PMID:11821431)
• two SNPs in the E-selectin gene and six SNPs in the L-selectin gene were significantly associated with IgAN in Japanese patients (PMID:11828340)
• L-selectin dimerization enhances tether formation to properly spaced ligand. (PMID:11907045)
• destabilization of L-selectin-mediated lymphocyte rolling by endothelial chemokines (PMID:12042326)
• does not play a role in homing and clonogenic outgrowth of CD34(+) peripheral blood stem cells (PMID:12063026)
• review of structure, function, cell and tissue distribution (PMID:12144128)
• Data show that tumor necrosis factor-alpha-converting enzyme (TACE)is involved in the shedding of L-selectin by NSAIDS in human neutrophils. (PMID:12147693)
• CD62L on human cultured T lymphoblasts is one of several glycoproteins that interacts directly with E-selectin and contributes to rolling under flow. (PMID:12165498)
• circulating soluble selectitn L in acute myeloid leukemia is correlaed with peripheral blast cell counts, extramedullaary infiltration, relapse and mortality (PMID:12186696)
• Protein polymorphism is associated with diabetic nephropathy in type 2 diabetes mellitus (PMID:12200076)
• Conjunctival biopsies excised from patients following cataract surgery provided circumstantial evidence that endothelial L-selectin might play a role in the surgery-induced up-regulation of leukocyte rolling. (PMID:12200386)
• data provide a comprehensive comparison of the L-selectin/cytoskeletal interaction with other functionally important surface antigens (PMID:12202158)
• L-selectin initiates leukocyte/endothelial cell interactions leading to leukocyte rolling and migration which are then optimized by CD18 integrin/ICAM-1 cooperative interactions. (PMID:12370391)
• that L-selectin was colocalized with high-affinity CD18.Adhesion signaled via L-selectin coincided with the kinetics of MAPK phosphorylation and was inhibited by blocking p38 or p42/44 activity. (PMID:12431911)
• L-selectin is expressed in memory CD4+ T cells that are smaller, proliferate well in response to tetanus toxoid, have longer telomeres, and express genes and proteins consistent with immune surveillance function. (PMID:12496379)
• results suggest that trophoblast L-selectin mediates interactions with the uterus and that this adhesion mechanism may be critical to establishing human pregnancy (PMID:12532021)
• L-selectin mobilized intracellular CXCR4 to significantly increase surface CXCR4 stimulation and inhibited SDF-1 induced CXCR4 internalization. (PMID:12609846)
• L-selectin binds with high affinity to the N-terminal region of PSGL-1 through cooperative interactions with three sulfated tyrosine residues and an appropriately positioned C2-O-sLex O-glycan. (PMID:12736247)
• interacts with Helicobacter pylori isolates from patients with chronic gastritis, duodenal ulcer and gastric cancer (PMID:12738381)
• Monitoring of the plasma level of sL-selectin is possibly useful for early diagnosis of relapse and extramedullary infiltration in acute leukemia. (PMID:12844406)
• Anaplasma phagocytophilum infected neutrophils showed reduced expression of P-selectin glycoprotein ligand 1 (PSGL-1, CD162) and L-selectin (CD62L) (PMID:12874338)
• expression on leukocytes in Behcet’s disease. (PMID:12918706)
• Strong relationship between soluble L-selectin and diabetic retinopathy. strong correlation between sL-selectin and HbA1c. Soluble L-selectin is increased with poor glycemic control. (PMID:14533031)
• engagement of both CD4 and CXCR4 is required for HIV-induced shedding of L-selectin on primary resting CD4(+) T cells. (PMID:14576059)
• Importance of CD62L expression on lymphocytes for recurrent miscarriage and the relevance of the maternal response to microbial antigens during pregnancy should be further explored. (PMID:14585903)
• L-selectin tethers appear adapted to undergo rapid avidity enhancement by cellular transport, a specialized mechanism not used by any other known adhesion receptor. (PMID:14597772)
• L-selectin mediates adhesion at all shear rates. Mocyte-expressed L-selectin functionally mediates primary tethering of monocytes to endothelial-cell ccarbohydrate ligands. L-selectin blockade without PMCs had an inhibitory effect on monocyte adhesion. (PMID:14615387)
• positive marker for precinical type 1 diabetes in children (PMID:14737745)
• LSEL expression is increased by biochemical engineering of sialic acids. (PMID:15093751)
• results suggest that ezrin-radixin-moesin proteins are required for microvillar positioning of L-selectin and that this is important both for leukocyte tethering and L-selectin shedding (PMID:15178693)
• L-selectin signal transduction requires protein kinase C alpha, iota, and theta binding (PMID:15192100)
• L-selectin plays a role in the vascular homing of peripheral blood-derived endothelial progenitor cells. (PMID:15470072)
• describes currently known binding partners of the L-selectin tail and how their associations affect L-selectin function. (review) (PMID:15506984)
• There was significantly more soluble L-selectin in serum samples from subjects with cryptococcosis than in those from uninfected subjects (PMID:15776384)
• Increased expression of L-selectin ligand in the human endometrium during the early and midsecretory phases of the menstrual cycle may be related to the process of implantation. (PMID:15831305)
• Serum levels were measured with enzyme-linked immunosorbent assays over the first 2 years of life in 65 children seroconverting to positivity for autoantibodies and 65 control children, all with susceptibility to type 1 diabetes. (PMID:16270299)
• variant isoforms of CD44 on LS174T colon carcinoma cells possess selectin binding activity, in contrast to the standard isoform of CD44 on hematopoietic-progenitor cells. (PMID:16352650)
• The 206Leu allele frequency occurred in 42% of the patients with coronary artery disease compared to 30% of the controls (p<0.009). (PMID:16357481)
• expression of HCELL confers robust and predominant tumor cell binding to E- and L-selectin (PMID:16565092)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Sell	ENSMUSG00000026581
rattus_norvegicus	Sell	ENSRNOG00000002776

Paralogs (39): CFH (ENSG00000000971), SELE (ENSG00000007908), C8B (ENSG00000021852), C6 (ENSG00000039537), SEZ6 (ENSG00000063015), CFHR2 (ENSG00000080910), APOH (ENSG00000091583), SEZ6L (ENSG00000100095), SUSD6 (ENSG00000100647), SRPX (ENSG00000101955), SRPX2 (ENSG00000102359), C7 (ENSG00000112936), C9 (ENSG00000113600), PAPPA2 (ENSG00000116183), CFHR3 (ENSG00000116785), CR2 (ENSG00000117322), CD46 (ENSG00000117335), CSMD2 (ENSG00000121904), C4BPA (ENSG00000123838), C4BPB (ENSG00000123843), CFHR4 (ENSG00000134365), CFHR5 (ENSG00000134389), F13B (ENSG00000143278), SUSD4 (ENSG00000143502), C8A (ENSG00000157131), SUSD3 (ENSG00000157303), CSMD3 (ENSG00000164796), SVEP1 (ENSG00000165124), C2 (ENSG00000166278), SELP (ENSG00000174175), SEZ6L2 (ENSG00000174938), PRF1 (ENSG00000180644), PAPPA (ENSG00000182752), CSMD1 (ENSG00000183117), CD55 (ENSG00000196352), CR1L (ENSG00000197721), CR1 (ENSG00000203710), CFB (ENSG00000243649), CFHR1 (ENSG00000244414)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:98279) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 37 distinct phenotype terms.

Mouse phenotype (MP)	Records
impaired leukocyte tethering or rolling	7
abnormal leukocyte migration	4
lymph node hypoplasia	3
abnormal cellular extravasation	3
increased monocyte cell number	2
enlarged spleen	2
spleen hyperplasia	2
abnormal hypersensitivity reaction	2
abnormal neutrophil physiology	2
decreased single-positive T cell number	2
decreased monocyte cell number	1
extramedullary hematopoiesis	1
decreased metastatic potential	1
decreased activated T cell number	1
increased inflammatory response	1
pancreas inflammation	1
decreased tumor incidence	1
abnormal dendritic cell physiology	1
abnormal cell-mediated immunity	1
abnormal granulocyte physiology	1
abnormal type IV hypersensitivity reaction	1
abnormal leukocyte adhesion	1
increased tumor growth/size	1
decreased susceptibility to autoimmune diabetes	1
abnormal regulatory T cell physiology	1

+12 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Papio hamadryas	Q28768	99.7%	Diamond
Macaca mulatta	Q95198	99.7%	Diamond
Pan troglodytes	Q95237	99.7%	Diamond
Pongo pygmaeus	Q95235	98.9%	Diamond
Equus caballus	Q95LG1	82.2%	Diamond
Canis lupus familiaris	P33730	80.6%	Diamond
Bos taurus	P98131	78.7%	Diamond
Ovis aries	P98109	76.5%	Diamond
Oryctolagus cuniculus	P27113	67.6%	Diamond
Sus scrofa	P98110	62.0%	Diamond
Danio rerio	A0A1D5NSM8	54.8%	Diamond
Drosophila melanogaster	Q09101	40.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
FIRRM	protein-coding	55732
SCYL3	protein-coding	57147
SELE	protein-coding	6401
METTL18	protein-coding	92342
F5	protein-coding	2153
SELP	protein-coding	6403
SLC19A2	protein-coding	10560

Protein

Protein identifiers

L-selectin — P14151 (reviewed: P14151)

Alternative names: CD62 antigen-like family member L, Leukocyte adhesion molecule 1, Leukocyte surface antigen Leu-8, Leukocyte-endothelial cell adhesion molecule 1, Lymph node homing receptor, TQ1, gp90-MEL

All UniProt accessions (2): A0A494C0S7, P14151

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-dependent lectin that mediates cell adhesion by binding to glycoproteins on neighboring cells. Mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes. Promotes initial tethering and rolling of leukocytes in endothelia.

Subunit / interactions. Interaction with SELPLG/PSGL1 and PODXL2 is required for promoting recruitment and rolling of leukocytes. This interaction is dependent on the sialyl Lewis X glycan modification of SELPLG and PODXL2, and tyrosine sulfation modifications of SELPLG. Sulfation on ‘Tyr-51’ of SELPLG is important for L-selectin binding.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in B-cell lines and T-lymphocytes.

Post-translational modifications. N-glycosylated.

Similarity. Belongs to the selectin/LECAM family.

Isoforms (2)

UniProt ID	Names	Canonical?
P14151-1	1	yes
P14151-2	2

RefSeq proteins (1): NP_000646* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000436	Sushi_SCR_CCP_dom	Domain
IPR000742	EGF	Domain
IPR001304	C-type_lectin-like	Domain
IPR002396	Selectin_superfamily	Family
IPR016186	C-type_lectin-like/link_sf	Homologous_superfamily
IPR016187	CTDL_fold	Homologous_superfamily
IPR016348	L-selectin	Family
IPR018378	C-type_lectin_CS	Conserved_site
IPR033991	Selectin_CTLD	Domain
IPR035976	Sushi/SCR/CCP_sf	Homologous_superfamily
IPR050350	Compl-Cell_Adhes-Reg	Family

Pfam: PF00008, PF00059, PF00084

UniProt features (61 total): strand 11, disulfide bond 9, glycosylation site 6, binding site 5, sequence conflict 5, sequence variant 4, mutagenesis site 4, helix 4, domain 4, topological domain 2, turn 2, signal peptide 1, propeptide 1, chain 1, splice variant 1, transmembrane region 1

Structure

Experimental structures (PDB)

3 structures by resolution:

PDB	Title	Method	Resolution (Å)
5VC1	Crystal structure of L-selectin lectin/EGF domains	X-RAY DIFFRACTION	1.94
3CFW	L-selectin lectin and EGF domains	X-RAY DIFFRACTION	2.2
2LGF	Solution structure of Ca2+/calmodulin complexed with a peptide representing the …	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P14151-F1	84.76	0.69

Human Protein Atlas

Protein class: CD markers, Predicted membrane proteins, Predicted intracellular proteins, Plasma proteins, Cancer-related genes, Candidate cancer biomarkers, Candidate cardiovascular disease genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): cytosol

Antibody reliability (HPA): IH enhanced · IF uncertain

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (5)

Position	Role
118	Ca(2+)
120	Ca(2+)
126	Ca(2+)
143	Ca(2+)
144	Ca(2+)

Disulfide bonds (9)

Type	Positions
Disulfide bond	57–155, 128–147, 160–171, 165–180, 182–191, 197–241, 227–254, 259–303, 289–316

Glycosylation sites (6)

Type	Positions
N-linked (glcnac…) asparagine	60, 104, 177, 232, 246, 271

Mutagenesis-validated functional residues (4)

Position	Phenotype
60	loss of one glycosylation site.
104	loss of one glycosylation site.
126	impairs interaction with cognate oligosaccharide. abolishes cell rolling on glycan ligands.
177	loss of one glycosylation site.

Function

Pathways and Gene Ontology

Reactome pathways

3 curated (TAS) of 7; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

7 pathways:

ID	Pathway	Evidence
R-HSA-202733	Cell surface interactions at the vascular wall	curated
R-HSA-198933	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	curated
R-HSA-6798695	Neutrophil degranulation	curated
R-HSA-1280218	Adaptive Immune System	—
R-HSA-109582	Hemostasis	—
R-HSA-168256	Immune System	—
R-HSA-168249	Innate Immune System	—

MSigDB gene sets: 398 (showing top): WALLACE_PROSTATE_CANCER_RACE_UP, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, LU_IL4_SIGNALING, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOCC_SECRETORY_GRANULE, CHIARETTI_T_ALL_REFRACTORY_TO_THERAPY, CHUNG_BLISTER_CYTOTOXICITY_DN, MODULE_45, MODULE_64, GOZGIT_ESR1_TARGETS_DN, IVANOVA_HEMATOPOIESIS_LATE_PROGENITOR, GOCC_CELL_SURFACE, GNF2_LYN

GO Biological Process (7): cell adhesion (GO:0007155), heterophilic cell-cell adhesion (GO:0007157), leukocyte cell-cell adhesion (GO:0007159), calcium-dependent cell-cell adhesion (GO:0016339), response to cytokine (GO:0034097), leukocyte tethering or rolling (GO:0050901), leukocyte migration (GO:0050900)

GO Molecular Function (10): protease binding (GO:0002020), calcium ion binding (GO:0005509), heparin binding (GO:0008201), carbohydrate binding (GO:0030246), sialic acid binding (GO:0033691), glycosphingolipid binding (GO:0043208), oligosaccharide binding (GO:0070492), protein binding (GO:0005515), metal ion binding (GO:0046872), cell adhesion molecule binding (GO:0050839)

GO Cellular Component (5): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), secretory granule membrane (GO:0030667), cell surface (GO:0009986), membrane (GO:0016020)

Reactome top-level categories

4 top-level categories:

Category	Pathways
Immune System	2
Adaptive Immune System	1
Hemostasis	1
Innate Immune System	1

GO top-level categories

28 GO namespaces:

Category	Terms
cell-cell adhesion	3
binding	2
cellular anatomical structure	2
cellular process	1
response to peptide	1
cellular extravasation	1
leukocyte adhesion to vascular endothelial cell	1
immune system process	1
cell migration	1
enzyme binding	1
metal ion binding	1
glycosaminoglycan binding	1
sulfur compound binding	1
carboxylic acid binding	1
carbohydrate derivative binding	1
sphingolipid binding	1
glycolipid binding	1
carbohydrate binding	1
cation binding	1
protein binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
secretory granule	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 6 of 23 annotations. The rest are phylogenetic / computational / electronic (IEA).

6 experimentally-supported GO terms:

GO term	NS	Evidence
calcium-dependent cell-cell adhesion	BP	mutant phenotype
leukocyte tethering or rolling	BP	mutant phenotype
plasma membrane	CC	direct assay
calcium ion binding	MF	direct assay
oligosaccharide binding	MF	mutant phenotype
protease binding	MF	physical interaction

Protein interactions and networks

STRING

showing 16 of 2,780 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SELL	CD44	P16070	920
SELL	CD4	P01730	919
SELL	CD8A	P01732	919
SELL	CCR7	P32248	915
SELL	ITGAM	P11215	915
SELL	CD69	Q07108	885
SELL	IFNG	P01579	862
SELL	FOXP3	Q9BZS1	861
SELL	PTPRC	P08575	859
SELL	ITGB2	P05107	845
SELL	IL7R	P16871	804
SELL	CD19	P15391	804
SELL	S1PR1	P21453	801
SELL	IL2	P01585	798
SELL	FCGR3A	P08637	797
SELL	FCGR3B	O75015	797

IntAct

Human interaction partners of SELL in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

3 partners by confidence:

Partner	Interaction type	MIscore	Records
CD34	direct interaction	0.440	1
PODXL	direct interaction	0.440	1
SELPLG	direct interaction	0.440	1

BioGRID (18 interactions; top human partners by supporting records): PRKCA (Biochemical Activity; 3 records), CFH (Reconstituted Complex), DDX58 (Affinity Capture-RNA), EMCN (Affinity Capture-Western), EZR (Reconstituted Complex), GRB2 (Affinity Capture-Western), MSN (Reconstituted Complex), MUC7 (Reconstituted Complex), PODXL (Affinity Capture-Western), PODXL2 (Reconstituted Complex), PRKCQ (Reconstituted Complex), PRKG1 (Biochemical Activity), SELE (Affinity Capture-Luminescence), SLC30A2 (Two-hybrid), SRGN (Affinity Capture-MS)

SIGNOR signaling

2 signaling interactions:

A	Effect	B	Mechanism
C5AR2	“down-regulates quantity by repression”	SELL
C5AR1	“down-regulates quantity by repression”	SELL

Ligand–receptor pairs (CellPhoneDB) (4)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

4 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
CD34	receptor
PODXL2	receptor	Signaling by Podocalyxin-like protein
PODXL	receptor	Signaling by Podocalyxin-like protein
SELPLG	receptor	Signaling by Selectin

Disease & clinical

Genetic variants

Variant evidence for SELL: 61 ClinVar records (1 pathogenic / likely pathogenic); 11 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	49
Likely benign	2
Benign	4

Top pathogenic / likely-pathogenic (1)

Showing all 1 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
1457087	NC_000001.10:g.(?169660781)(170521603_?)del	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore SELL’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 20 predictions of 847):

Position(s)	Effect	Δscore	Sites
1:169704567	donor_loss	1.0000
1:169704758–169704759	acceptor_gain	1.0000	2
1:169707463	acceptor_gain	1.0000
1:169710434–169710435	donor_loss	1.0000	4
1:169710519	acceptor_loss	1.0000
1:169710524	acceptor_gain	1.0000
1:169703445–169703446	acceptor_gain	0.9900	2
1:169704566–169704567	donor_loss	0.9900	2
1:169704754–169704755	acceptor_loss	0.9900	5
1:169710411	donor_gain	0.9900

AlphaMissense

641 missense substitutions predicted likely pathogenic (of 2,479 scored), across 149 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
N143	8	0.950	0.988
D144	8	0.934	0.987
D63	8	0.848	0.958
D145	8	0.766	0.914
W142	7	0.989	0.999
C57	7	0.987	0.994
W114	7	0.987	0.999
C128	7	0.987	0.994
C155	7	0.985	0.994
W98	7	0.977	0.996
C147	7	0.975	0.986
W88	7	0.974	0.995
C160	7	0.958	0.974
W100	7	0.955	0.994
E130	7	0.952	0.984
C191	7	0.950	0.981
W50	7	0.949	0.994
C171	7	0.948	0.979
E118	7	0.936	0.980
C180	7	0.935	0.963

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

4 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Papillary Cell Carcinoma (TCGA)	unfavorable	0.000533
Liver Hepatocellular Carcinoma (TCGA)	favorable	0.000549
Breast Invasive Carcinoma (TCGA)	favorable	0.000741
Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA)	favorable	0.000969

Disease associations

OMIM: gene MIM:153240 | disease phenotypes:

GWAS associations

11 associations:

Study	Trait	p-value
GCST006585_775	Blood protein levels	6e-48
GCST010107_13	L-selectin levels	7e-20
GCST90002393_331	Monocyte count	4e-11
GCST90002382_40	Eosinophil percentage of white cells	6e-11
GCST90002380_2	Basophil percentage of white cells	7e-10
GCST002329_1	Acne (severe)	1e-8
GCST010107_18	L-selectin levels	1e-8
GCST003043_184	Inflammatory bowel disease	3e-8
GCST010107_10	L-selectin levels	1e-7
GCST010107_3	L-selectin levels	2e-6
GCST000406_8	Amyotrophic lateral sclerosis	4e-6

EFO canonical traits (from GWAS)

4 canonical traits:

EFO ID	Trait name
EFO:0008202	L-Selectin measurement
EFO:0007992	basophil percentage of leukocytes
EFO:0007991	eosinophil percentage of leukocytes
EFO:0005091	monocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3161 (SINGLE PROTEIN), CHEMBL3831288 (PROTEIN FAMILY)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the SELL protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

2 curated-mechanism drugs:

Drug	Modality	Max phase
RIVIPANSEL	Small molecule	3
ASELIZUMAB	Antibody	2

Drugs acting on a complex or family that includes this protein

Curated ChEMBL mechanism-of-action drugs whose target is a protein complex or family of ≤10 members that includes SELL — the drug acts on the assembly or class, not necessarily on this subunit alone.

1 drugs via a complex or family:

Drug	Target (ChEMBL)	Members	Max phase
BIMOSIAMOSE	Selectin	3	2

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 104,183 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

1 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL288114	GALLIC ACID	2	104,183

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

50 measured of 85 human assays (86 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
3-[2-(3,4,5-trihydroxy-phenyl)-acetylamino]-benzoic acid	IC50	800 nM
{3-[2-(3,4,5-trihydroxy-phenyl)-acetylamino]-phenyl}-acetic acid	IC50	1000 nM
4-methyl-3-[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-benzoic acid	IC50	1300 nM
{3-[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-phenyl}-acetic acid	IC50	2300 nM
4-{[2-(3,4,5-trihydroxy-phenyl)-acetylamino]-methyl}-cyclohexanecarboxylic acid	IC50	3000 nM
4-{[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-methyl}-cyclohexanecarboxylic acid	IC50	3100 nM
(5-{2-[2-(3,4,5-trihydroxy-phenyl)-acetylamino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	3300 nM
(R)-4-Methylcarbamoyl-4-[(S)-2-(2-tetradecyl-hexadecanoylamino)-3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-propionylamino]-butyric acid	IC50	3500 nM
CHEMBL2303755	IC50	3500 nM
(2’-{[(3,4,5-trihydroxyphenyl)acetyl]amino}-1,1’-biphenyl-3-yl)acetic acid	IC50	4900 nM
4-{[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-methyl}-benzoic acid	IC50	8400 nM
2-methyl-3-[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-benzoic acid	IC50	8400 nM
4-{[2-(3,4,5-trihydroxy-phenyl)-acetylamino]-methyl}-benzoic acid	IC50	8700 nM
(5-{4-[(2’,3’,4’-trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	9700 nM
Gallic Acid, F	IC50	14000 nM
(5-{3-[(2’,3’,4’-trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	15700 nM
3-[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-benzoic acid	IC50	18700 nM
Sodium; 3,5-dihydroxy-2-[5-hydroxy-2-hydroxymethyl-6-(2-tetradecyl-hexadecyloxy)-4-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yloxy]-6-hydroxymethyl-tetrahydro-pyran-4-sulfonate	IC50	30000 nM
5-methylbenzene-1,2,3-triol	IC50	31700 nM
(5-{2-[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	41900 nM
(5-{2-[(2’,3’,4’-trihydroxy-biphenyl-4-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	48000 nM
(5-{2-[3-(3,4,5-trihydroxy-phenyl)-acryloylamino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	48600 nM
(5-{2-[4-(3,4,5-trihydroxy-phenyl)-butyrylamino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	52400 nM
(5-{2-[3-(2,3,4-trihydroxy-phenyl)-acryloylamino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	57200 nM
5-{2-[(2'3’,4’-hydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophene-2-carboxylic acid	IC50	61400 nM
{2’-[3-(3,4,5-trihydroxy-phenyl)-propionylamino]-biphenyl-3-yl}-acetic acid	IC50	85400 nM
(5-{2-[(3’,4’,5’-trihydroxy-biphenyl-2-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	114000 nM
(5-{2-[(2’,3’,4’-trihydroxy-biphenyl-3-carbonyl)-amino]-phenyl}-thiophen-2-yl)-acetic acid	IC50	132000 nM
5-Acetylamino-2-{2-[5-acetylamino-2-hydroxy-4-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yloxy]-3,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-4-yloxy}-4-hydroxy-6-(1,2,3-trihydroxy-propyl)-tetrahydro-pyran-2-carboxylic acid	IC50	134000 nM
4-Methylcarbamoyl-4-[(R)-3-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2-(2-undecyl-tridecanoylamino)-propionylamino]-butyric acid	IC50	160000 nM
5-Acetylamino-2-{2-[2,5-dihydroxy-4-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yloxy]-3,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-4-yloxy}-4-hydroxy-6-(1,2,3-trihydroxy-propyl)-tetrahydro-pyran-2-carboxylic acid	IC50	240000 nM
CHEMBL2029056	IC50	280000 nM
CHEMBL2303879	IC50	300000 nM
CHEMBL2303852	IC50	330000 nM
5-Acetylamino-2-{3,5-dihydroxy-2-hydroxymethyl-6-[2-hydroxymethyl-4-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yloxy]-tetrahydro-pyran-4-yloxy}-4-hydroxy-6-((1R,2R)-1,2,3-trihydroxy-propyl)-tetrahydro-pyran-2-carboxylic acid	IC50	360000 nM
CHEMBL2303890	IC50	400000 nM
CHEMBL2303886	IC50	500000 nM
CHEMBL2303881	IC50	500000 nM
CHEMBL2303876	IC50	500000 nM
5-Acetylamino-2-(3,5-dihydroxy-2-hydroxymethyl-6-N-[2,5-Dihydroxy-6-hydroxymethyl-4-(3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-tetrahydro-pyran-3-yl]-acetamide-tetrahydro-pyran-4-yloxy)-4-hydroxy-6-(1,2,3-trihydroxy-propyl)-tetrahydro-pyran-2-carboxylic acid	IC50	600000 nM
CHEMBL2303893	IC50	1e+06 nM
CHEMBL2303868	IC50	1e+06 nM
CHEMBL2303877	IC50	1e+06 nM
Sialyl LeX	IC50	1.09e+06 nM
CHEMBL2303887	IC50	2e+06 nM
CHEMBL2303888	IC50	2e+06 nM
CHEMBL2303889	IC50	3e+06 nM
CHEMBL2303882	IC50	3.2e+06 nM
CHEMBL2303867	IC50	4e+06 nM
CHEMBL2303872	IC50	5e+06 nM

ChEMBL bioactivities

29 potent at pChembl≥5 of 51 total, top 29 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.16	IC50	700	nM	CHEMBL3351094
6.10	IC50	800	nM	CHEMBL3351095
6.10	IC50	790	nM	CHEMBL375763
6.00	IC50	1000	nM	CHEMBL112796
5.96	IC50	1100	nM	CHEMBL220720
5.85	IC50	1400	nM	CHEMBL221163
5.82	IC50	1500	nM	CHEMBL220254
5.80	IC50	1600	nM	CHEMBL3351093
5.80	IC50	1600	nM	CHEMBL223010
5.80	IC50	1600	nM	CHEMBL373592
5.75	IC50	1800	nM	CHEMBL3351089
5.64	IC50	2300	nM	CHEMBL220419
5.63	IC50	2340	nM	CHEMBL3215517
5.62	IC50	2400	nM	CHEMBL450011
5.52	IC50	3000	nM	CHEMBL112485
5.51	IC50	3100	nM	CHEMBL2303665
5.51	IC50	3100	nM	CHEMBL386951
5.48	IC50	3300	nM	CHEMBL220997
5.42	IC50	3800	nM	CHEMBL133134
5.40	IC50	4000	nM	CHEMBL2303755
5.40	IC50	4000	nM	CHEMBL3215516
5.38	IC50	4200	nM	CHEMBL2303665
5.38	IC50	4200	nM	CHEMBL220560
5.37	IC50	4300	nM	CHEMBL220340
5.36	IC50	4400	nM	CHEMBL2303665
5.24	IC50	5700	nM	CHEMBL376200
5.06	IC50	8700	nM	CHEMBL220828
5.01	IC50	9700	nM	CHEMBL426376
5.01	IC50	9800	nM	CHEMBL386952

PubChem BioAssay actives

29 with measured affinity, of 143 total; 27 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(4R)-5-(methylamino)-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202721: Inhibition of Selectin L binding	ic50	0.7000	uM
2-[5-[4-[[3-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophen-2-yl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	0.7900	uM
(4R)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202721: Inhibition of Selectin L binding	ic50	0.8000	uM
1-[4-methoxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]phenyl]cyclohexane-1-carboxylic acid	95568: Inhibitory activity against L-selectin IgG chimeras binding to sLex coating 96 wells using competitive cell-free ELISA assay was determined.	ic50	1.0000	uM
2-[5-[3-[[3-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophen-2-yl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	1.1000	uM
3-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]benzoic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	1.4000	uM
2-[3-[2-(3,4,5-trihydroxybenzoyl)oxyphenyl]phenyl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	1.5000	uM
(4S)-5-(methylamino)-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202721: Inhibition of Selectin L binding	ic50	1.6000	uM
5-[2-[[3-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophene-2-carboxylic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	1.6000	uM
2-[5-[2-[[4-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophen-2-yl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	1.6000	uM
(4S)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4S,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypropanoyl]amino]pentanoic acid	202721: Inhibition of Selectin L binding	ic50	1.8000	uM
2-[3-[3-(3,4,5-trihydroxyphenyl)propanoylamino]phenyl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	2.3000	uM
3-[(2S,5R)-3,6-dioxo-7-(2-tetradecylhexadecyl)-5-[[(2S,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-1,4,7-thiadiazecan-2-yl]propanoic acid	202718: In vitro inhibitory activity of compound was determined against Selectin L binding by ELISA assay	ic50	2.3400	uM
5-methoxy-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxypropanoyl]amino]pentanoic acid	202721: Inhibition of Selectin L binding	ic50	2.4000	uM
2-[4-methoxy-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)phenyl]acetic acid	95568: Inhibitory activity against L-selectin IgG chimeras binding to sLex coating 96 wells using competitive cell-free ELISA assay was determined.	ic50	3.0000	uM
2-[5-[2-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]phenyl]thiophen-2-yl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	3.1000	uM
(4R)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoyl]amino]pentanoic acid	202721: Inhibition of Selectin L binding	ic50	3.1000	uM
4-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]cyclohexane-1-carboxylic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	3.3000	uM
4-(methylamino)-4-oxo-3-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxypropanoyl]amino]butanoic acid	202721: Inhibition of Selectin L binding	ic50	3.8000	uM
(4S)-5-(methylamino)-5-oxo-4-[[(2R)-2-(2-tetradecylhexadecanoylamino)-3-[(2S,3S,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoyl]amino]pentanoic acid	202721: Inhibition of Selectin L binding	ic50	4.0000	uM
(4R)-5-(methylamino)-5-oxo-4-[[(2S)-2-(2-tetradecylhexadecanoylamino)-3-[(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoyl]amino]pentanoic acid	202718: In vitro inhibitory activity of compound was determined against Selectin L binding by ELISA assay	ic50	4.0000	uM
4-methyl-3-[3-(3,4,5-trihydroxyphenyl)propanoylamino]benzoic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	4.2000	uM
2-[5-[2-[[(E)-3-(2,3,4-trihydroxyphenyl)prop-2-enoyl]amino]phenyl]thiophen-2-yl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	4.3000	uM
4-[3-(3,4,5-trihydroxyphenyl)propanoylamino]cyclohexane-1-carboxylic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	5.7000	uM
2-[3-[2-[[2-(3,4,5-trihydroxyphenyl)acetyl]amino]phenyl]phenyl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	8.7000	uM
2-[5-[2-[[2-[3-(2,3,4-trihydroxyphenyl)phenyl]acetyl]amino]phenyl]thiophen-2-yl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	9.7000	uM
2-[5-[2-[[3-(2,3,4-trihydroxyphenyl)benzoyl]amino]phenyl]thiophen-2-yl]acetic acid	280293: Inhibition of human L-selectin after 2 hrs	ic50	9.8000	uM

CTD chemical–gene interactions

73 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Calcimycin	decreases expression, affects cotreatment, decreases reaction, increases expression	2
Resveratrol	decreases reaction, increases expression, decreases expression	2
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	2
Heparin	decreases expression, increases expression	2
Indomethacin	decreases expression	2
Lipopolysaccharides	decreases expression	2
Methotrexate	decreases expression	2
Plant Extracts	decreases reaction, increases expression	2
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	2
Tretinoin	increases expression	2
GSK-J4	decreases expression	1
fulvic acid	affects cotreatment, decreases reaction, increases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	affects cotreatment, increases expression, decreases reaction	1
Lipofundin	decreases expression	1
nimesulide	decreases expression	1
afimoxifene	increases expression	1
sodium arsenite	increases expression	1
endotoxin, Escherichia coli	increases expression, decreases reaction, affects cotreatment	1
aceclofenac	decreases expression	1
N,N-diacetylcystine	decreases expression	1
tamibarotene	increases expression	1
quinupristin-dalfopristin	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
lipopolysaccharide, E. coli O26-B6	decreases expression, decreases reaction	1
abrine	decreases expression	1
3,5-bis(2-fluorobenzylidene)piperidin-4-one	decreases reaction, increases expression	1
Decitabine	increases expression	1
Zoledronic Acid	increases expression	1

ChEMBL screening assays

16 unique, capped per target: 16 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4264750	Binding	Inhibition of human L-selectin transfected in mouse 300.19 cells assessed as decrease in protein-mediated cell rolling on GlyCAM-1 or PNAd preincubated for 5 mins followed by cell perfusion through laminar flow chamber coated with GlyCAM-1	Chemistry-driven glycoscience. — *Bioorg Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for SELL across ~30M SureChEMBL compounds — explore on Sugi Predict.